

Eleni-Rosalina Andrinopoulou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6169464/publications.pdf>

Version: 2024-02-01

90
papers

4,451
citations

109321

35
h-index

118850

62
g-index

93
all docs

93
docs citations

93
times ranked

6433
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	7.6	448
2	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	10.2	394
3	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	7.7	210
4	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015, 85, 1276-1282.	1.1	197
5	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014, 10, 477.	0.8	167
6	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. <i>NeuroImage: Clinical</i> , 2014, 4, 164-173.	2.7	112
7	Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. <i>Acta Neuropathologica</i> , 2018, 136, 377-388.	7.7	112
8	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 864-870.	1.9	105
9	Evaluating the Patterns of Aging-Related Tau Astroglial Pathology Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 270-288.	1.7	98
10	A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. <i>European Journal of Cancer</i> , 2014, 50, 267-276.	2.8	97
11	Olfactory impairment predicts cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 45-51.	2.2	97
12	Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3615-3620.	1.6	95
13	Differential α -synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. <i>Acta Neuropathologica</i> , 2018, 135, 855-875.	7.7	94
14	Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. <i>Movement Disorders</i> , 2015, 30, 912-918.	3.9	91
15	Long-term chamomile (<i>Matricaria chamomilla</i> L.) treatment for generalized anxiety disorder: A randomized clinical trial. <i>Phytomedicine</i> , 2016, 23, 1735-1742.	5.3	88
16	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	5.3	88
17	Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. <i>Phytomedicine</i> , 2015, 22, 394-399.	5.3	85
18	Naltrexone for impulse control disorders in Parkinson disease. <i>Neurology</i> , 2014, 83, 826-833.	1.1	74

#	ARTICLE	IF	CITATIONS
19	New York City COVID-19 resident physician exposure during exponential phase of pandemic. <i>Journal of Clinical Investigation</i> , 2020, 130, 4726-4733.	8.2	72
20	CSF tau and β -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018, 90, e1038-e1046.	1.1	68
21	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 987-994.	2.6	67
22	Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. <i>Movement Disorders</i> , 2015, 30, 1648-1656.	3.9	66
23	Building an integrated neurodegenerative disease database at an academic health center. <i>Alzheimer's and Dementia</i> , 2011, 7, e84-93.	0.8	63
24	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 2945-2950.	3.9	63
25	Neocortical origin and progression of gray matter atrophy in nonamnesic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 63, 75-87.	3.1	61
26	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. <i>Brain</i> , 2018, 141, 288-301.	7.6	56
27	Joint modeling of two longitudinal outcomes and competing risk data. <i>Statistics in Medicine</i> , 2014, 33, 3167-3178.	1.6	55
28	<i>TMEM106B</i> Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019, 85, 801-811.	5.3	52
29	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2017, 82, 247-258.	5.3	51
30	An Introduction to Mixed Models and Joint Modeling: Analysis of Valve Function Over Time. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1765-1772.	1.3	48
31	Semi-Automated Digital Image Analysis of Pick's Disease and TDP-43 Proteinopathy. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 54-66.	2.5	43
32	Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. <i>Annals of Neurology</i> , 2019, 85, 630-643.	5.3	40
33	Improved Dynamic Predictions from Joint Models of Longitudinal and Survival Data with Time-varying Effects Using P-splines. <i>Biometrics</i> , 2018, 74, 685-693.	1.4	39
34	Multisite Assessment of Aging-Related Tau Astroglipathy (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	1.7	38
35	Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. <i>Scientific Reports</i> , 2016, 5, 18286.	3.3	37
36	Longitudinal progression of grey matter atrophy in non-amnesic Alzheimer's disease. <i>Brain</i> , 2019, 142, 1701-1722.	7.6	37

#	ARTICLE	IF	CITATIONS
37	Bayesian shrinkage approach for a joint model of longitudinal and survival outcomes assuming different association structures. <i>Statistics in Medicine</i> , 2016, 35, 4813-4823.	1.6	36
38	Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 339-348.	2.4	35
39	<i>APOE</i>, thought disorder, and SPAREAD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	3.9	35
40	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. <i>Acta Neuropathologica Communications</i> , 2017, 5, 68.	5.2	34
41	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	12.8	34
42	Regional brain amyloid- β^2 accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017, 12, e0177924.	2.5	33
43	Putative Antidepressant Effect of Chamomile (<i>Matricaria chamomilla</i> L.) Oral Extract in Subjects with Comorbid Generalized Anxiety Disorder and Depression. <i>Journal of Alternative and Complementary Medicine</i> , 2020, 26, 815-821.	2.1	33
44	Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration. <i>Neurology</i> , 2015, 84, 2070-2075.	1.1	30
45	Expectancy in Real and Sham Electroacupuncture: Does Believing Make It So?. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 302-307.	2.1	29
46	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	7.7	29
47	Amyloid- β Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 367-375.	1.5	28
48	Combined dynamic predictions using joint models of two longitudinal outcomes and competing risk data. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1787-1801.	1.5	27
49	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 119-124.	2.2	26
50	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. <i>PLoS ONE</i> , 2016, 11, e0147319.	2.5	25
51	Dynamic prediction of outcome for patients with severe aortic stenosis: application of joint models for longitudinal and time-to-event data. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 28.	1.7	24
52	Cox Regression Model with Doubly Truncated Data. <i>Biometrics</i> , 2018, 74, 725-733.	1.4	24
53	Choosing Options for Insomnia in Cancer Effectively (CHOICE): Design of a patient centered comparative effectiveness trial of acupuncture and cognitive behavior therapy for insomnia. <i>Contemporary Clinical Trials</i> , 2016, 47, 349-355.	1.8	23
54	Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 30.	5.2	22

#	ARTICLE	IF	CITATIONS
55	Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 278-286.	1.8	21
56	Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 1691-1699.	1.6	19
57	Reflection on modern methods: Dynamic prediction using joint models of longitudinal and time-to-event data. <i>International Journal of Epidemiology</i> , 2021, 50, 1731-1743.	1.9	19
58	Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. <i>Movement Disorders</i> , 2017, 32, 1636-1640.	3.9	18
59	Occupational attainment influences longitudinal decline in behavioral variant frontotemporal degeneration. <i>Brain Imaging and Behavior</i> , 2019, 13, 293-301.	2.1	18
60	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	2.8	13
61	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 682.	2.8	13
62	Long-Term Chamomile Therapy of Generalized Anxiety Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial. <i>Journal of Clinical Trials</i> , 2015, 04, .	0.1	12
63	Research consent capacity varies with executive function and memory in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 414-417.	3.9	12
64	Signature laminar distributions of pathology in frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2022, 143, 363-382.	7.7	12
65	Rhodiola Rosea Therapy for Major Depressive Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial. <i>Journal of Clinical Trials</i> , 2014, 04, 170.	0.1	11
66	Genetic predictors of survival in behavioral variant frontotemporal degeneration. <i>Neurology</i> , 2019, 93, e1707-e1714.	1.1	11
67	Meta-Analysis of Several Epidemic Characteristics of COVID-19. <i>Journal of Data Science</i> , 2020, 18, 536-549.	0.9	11
68	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	12.8	11
69	The Kaplan-Meier method for estimating and comparing proportions in a randomized controlled trial with dropouts. <i>Biostatistics and Epidemiology</i> , 2018, 2, 23-33.	0.4	9
70	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1155-1167.	2.8	9
71	Adjustment for measurement error in evaluating diagnostic biomarkers by using an internal reliability sample. <i>Statistics in Medicine</i> , 2013, 32, 4709-4725.	1.6	7
72	Assessing treatment effects with surrogate survival outcomes using an internal validation subsample. <i>Clinical Trials</i> , 2015, 12, 333-341.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). <i>Journal of Parkinson's Disease</i> , 2016, 6, 383-392.	2.8	7
74	Bias induced by ignoring double truncation inherent in autopsy-confirmed survival studies of neurodegenerative diseases. <i>Statistics in Medicine</i> , 2019, 38, 3599-3613.	1.6	7
75	Plasma α -MIA, α -CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease. <i>Annals of Neurology</i> , 2022, 92, 255-269.	5.3	7
76	Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau. <i>NeuroImage: Clinical</i> , 2021, 31, 102717.	2.7	6
77	Older Adult Normative Data for the Sniffin Sticks Odor Identification Test. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 254-258.	0.5	5
78	Cox regression model under dependent truncation. <i>Biometrics</i> , 2022, 78, 460-473.	1.4	5
79	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 737-745.	2.8	5
80	Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 411-430.	2.2	4
81	Nonparametric discrete survival function estimation with uncertain endpoints using an internal validation subsample. <i>Biometrics</i> , 2015, 71, 772-781.	1.4	3
82	A Bayesian joint model for zero-inflated integers and left-truncated event times with a time-varying association: Applications to senior health care. <i>Statistics in Medicine</i> , 2021, 40, 147-166.	1.6	3
83	Measurement error reduction using weighted average method for repeated measurements from heterogeneous instruments. <i>Environmetrics</i> , 2001, 12, 785-790.	1.4	2
84	A Pragmatic Evaluation of the National Cancer Institute Physician Data Query (PDQ)-Based Brief Counseling on Cancer-Related Fatigue among Patients Undergoing Radiation Therapy. <i>Journal of Palliative Care & Medicine</i> , 2012, 02, .	0.1	2
85	Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2021, 108, 16-23.	3.1	2
86	Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 463-470.	2.6	1
87	IC-06: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON-AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P12.	0.8	0
88	P3-06: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON-AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1259.	0.8	0
89	Cognitive and neurodegenerative profile differences between α -mismatch MCI (A+T+N+ MCI) And α -prodromal AD (A+T+N+ MCI) increase with time. <i>Alzheimer's and Dementia</i> , 2020, 16, e046030.	0.8	0
90	Genetic and Neurophysiological Biomarkers of Neuroplasticity Inform Post-Stroke Language Recovery. <i>Neurorehabilitation and Neural Repair</i> , 2022, 36, 371-380.	2.9	0